Clinical Trial Update: A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial assesses safety, tolerability, and preliminary efficacy of lomvastomig, a PD-1/TIM-3 bispecific antibody, in adults with advanced and/or meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Lomvastomig (lomvastomig)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Solid Tumors, Metastatic Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2025-08-20